The Role of Nuclear Medicine in the Staging and Management of Liver Metastases

References

• DiChiro G., Dela Paz R., Brooks R. et al. Glucose utilization of cerebral gliomas measurement by [18F]fluorodeoxyglucose and positron emission tomography. Neurology, 1982, 32: 1323–1329.
   Google Scholar
• Gupta N. C., Frank A. R., Dewan N. A., Redepenning L. S., Rothberg M. L., Mailliard J. A., Phalen J. J., Sunderland J. J., Frick M. P. Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]fluoro-2-deoxy-d-glucose. Radiology, 1992, 184: 441–444.
   Google Scholar
• Zimny M., Bares R., Fab J. et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med, 1997, 24: 678–682.
   Google Scholar
• Vansteenkiste J. F., Stroobants S., Dupont P. et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol, 1999, 17: 3201–3206.
   Google Scholar
• MacFarlane D., Sondak V., Johnson T., Wahl R. Prospective evaluation of 2-[18F]-2-Deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol, 1998: 16: 1770–1776.
   Google Scholar
• Moog F., Bangerter M., Diederichs C. et al. Lymphoma: role of whole-body 2-deoxy-2-[F18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology, 1997, 203: 795–800.
   Google Scholar
• Weder W., Schmid R., Bruchhaus H. et al. Detection of extra-thoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg, 1998, 66: 886–893.
   Google Scholar
• Marom E., McAdams H., Erasmus J. et al. Staging non-small cell lung cancer with whole-body PET. Radiolology, 1999 212: 803809.
   Google Scholar
• Flamen P., Lerut A., Van-Cutsem E. et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol, 2000, 18: 32023210.
   Google Scholar
• Diederichs C., Staib L., Vogel J. et al. Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with pre-operative evaluation of patients with pancreatic masses. Pancreas, 2000, 20: 109–116.
   Google Scholar
• Frohlich A., Diederichs C., Staib L., Vogel J., Beger H., Reske S. Detection of liver metastases from pancreatic cancer using FDG PET. J Nucl Med, 1999, 40: 250–255.
   Google Scholar
• Shreve P. D., Grossman H. B., Gross M. D., Wahl R. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology, 1996, 199: 751–756.
   Google Scholar
• Adams S., Baum R., Rink Th., Schumm-Dräger P. M., Usadel Kl.-H., Hör G. Limited value of fluorine-18 fluorodeoxy-glucose positron emission tomography for the imaging of neuro-endocrine tumours. Eur J Nucl Med, 1998, 25: 79–83.
   Google Scholar
• Pasquali Cl., Rubello D., Sperti C., Gasparoni P., Liessi G., Chierichetti F., Ferlin G., Pedrazzoli S. Neuroendocrine Tumor Imaging: Can 18 F-Fluorodeoxyglucose Positron Emission Tomography Detect Tumors with Poor Prognosis and Aggressive Behavior? World J Surgery, 1998, 22: 588–592.
   Google Scholar
• Schiepers C., Penninckx F., De Vadder N., Merckx E., Mortelmans L., Bormans G. et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol, 1995, 21: 517–522.
   Google Scholar
• Arulampalam T., Costa D., Loizidou M., Visvikis D., Ell P. J. Positron emission tomography and colorectal cancer. Br J Surg, 2001, 88: 176–189.
   Google Scholar
• Flamen P., Stroobants S., Van Cutsem E., Dupont P., Bormans G., De Vadder N. et al. Additional value of whole-body positron emission tomography with fluorine-18-2-deoxy-d-glucose in recurrent colorectal cancer. J Clin Oncol, 1999, 17: 894–901.
   Google Scholar
• Beets G., Penninckx F., Schiepers C., Filez L., Mortelmans L., Kerremans R. et al. Clinical value of whole-body positron emission tomography with [18F] fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg, 1994, 81: 1666–1670.
   Google Scholar
• Delbeke D., Vitola J., Sandler M., Arildsen R., Powers T., Wright J. et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med, 1997, 38: 1196–1201.
   Google Scholar
• Flanagan F., Dehdashti F., Ogunbiyi O. et al. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg, 1998, 227: 319–323.
   Google Scholar
• Meta J., Seltzer M., Schiepers C. et al. Impact of 18F-FDG PET on managing patients with colorectal cancer: the referring physician’s perspective. J Nucl Med, 2001, 42: 586–590.
   Google Scholar
• Arulampalam T., Costa D., Visvikis D. et al. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer. Eur J Nucl Med, 2001, 28: 1758–1765.
   Google Scholar
• Ruers T., Langenhoff B., Neeleman N. et al. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol, 2002, 20: 388–395.
   Google Scholar
• Kalff V., Hicks R., Ware R. et al. The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med, 2002, 43: 492–499.
   Google Scholar
• Lonneux M., Reffad A. M., Detry R., Kartheuser A., Gigot J. F., Pauwels S. PET-FDG improves staging and selection of patients with recurrent colorectal cancer. Eur J Nucl Med, 2002, 29: 915921.
   Google Scholar
• Rydzewski B., Dehdashti F., Gordon B. et al. Usefulness of intra-operative sonography for revealing hepatic metastases from colorectal cancer in patients selected for surgery after undergoing FDG PET. AJR, 2002, 178: 353–358.
   Google Scholar
• Rohren E., Paulson R., Hagge R. et al. The role of F-18 FDG positron emission tomography in preoperative assesment of the liver in patients being considered for curative resection of hepatic metastases from colorectal cancer. Clin Nucl Med, 2002, 27: 550555.
   Google Scholar
• Goldberg R., Fleming T., Tangen C., Moertel C., MacDonald J., Haller D. et al. Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Ann Intern Med, 1998, 129: 27–35.
   Google Scholar
• Strasberg S., Dehdashti F., Siegel B. et al. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann Surg, 2001, 233: 293–299.
   Google Scholar
• Lonneux M., Borbath I., Berliere M., Kirkove C., Pauwels S. The place of whole body PET FDG for the diagnosis of distant recurrence of breast cancer. Clinical Positron Imaging, 2000, 3: 45–49.
   Google Scholar
• Lamberts S. W., Krenning E. P., Reubi J. C. The role of somato-statin and its analogs in the diagnosis and treatment of tumors. Endocr Rev, 1991, 12: 450–82.
   Google Scholar
• Krenning E. P., Kwekkeboom D. J., Bakker W. H., Breeman W. A., Kooij P. P., Oei H. Y., van Hagen M., Postema P. T., de Jong M., Reubi J. C. et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octre-otide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med, 1993, 20: 716–31.
   Google Scholar
• Gibril F., Reynolds J. C., Doppman J. L., Chen C. C., Venzon D. J., Termanini B., Weber H. C., Stewart C. A., Jensen R. T. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med, 1996, 125: 26–34.
   Google Scholar
• Jamar F., Fiasse R., Leners N., Pauwels S. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. J Nucl Med, 1995, 36: 542–9.
   Google Scholar
• Lebtahi R., Cadiot G., Sarda L., Daou D., Faraggi M., Petegnief Y., Mignon M., le Guludec D. Clinical impact of soma-tostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med, 1997, 38: 853–8.
   Google Scholar
• Moertel C. G., Kvols L. K., O’Connell M. J., Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer, 1991, 68: 227–32.
   Google Scholar
• de Jong M., Valkema R., Jamar F., Kvols L. K., Kwekkeboom D. J., Breeman W. A., Bakker W. H., Smith C., Pauwels S., Krenning E. P. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Sem Nucl Med, 2002, 32: 133–40.
   Google Scholar